Dorotea Gabel, MD
Internal Medicine · Spartanburg, SCNPI 1336110410
Payments from drug & device makers
Across 226 payments — averaging $15.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$491
- Amarin Pharma, Inc.$452
- AbbVie$279
- Astellas Pharma US Inc$241
- Pfizer$235
- Inari Medical, Inc.$199
- plus $2K from 30 others
What the payments were for
- Food & beverage$3,398100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 36 | $491 |
| Amarin Pharma, Inc. | 32 | $452 |
| AbbVie | 21 | $279 |
| Astellas Pharma US Inc | 15 | $241 |
| Pfizer | 21 | $235 |
| Inari Medical, Inc. | 2 | $199 |
| AstraZeneca | 13 | $171 |
| Novo Nordisk | 11 | $141 |
| Novartis | 8 | $131 |
| Sanofi-aventis U.S. LLC | 7 | $127 |
| GSK | 8 | $114 |
| Dexcom, Inc. | 6 | $103 |
| Boehringer Ingelheim | 6 | $84 |
| Lilly USA, LLC | 4 | $58 |
| Otsuka America Pharmaceutical, Inc. | 2 | $54 |
| Medtronic | 2 | $42 |
| Johnson & Johnson | 3 | $40 |
| Kowa Pharmaceuticals America, Inc. | 3 | $38 |
| Eisai Inc. | 3 | $37 |
| Abbott | 2 | $37 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $36 |
| Exact Sciences | 2 | $31 |
| Arbor Pharmaceuticals, Inc. | 2 | $31 |
| Merck | 2 | $28 |
| Edwards Lifesciences | 1 | $25 |
| Esperion Therapeutics, Inc. | 1 | $23 |
| Radius Health, Inc. | 1 | $22 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $19 |
| Phathom Pharmaceuticals, Inc. | 1 | $18 |
| Genentech USA, Inc. | 1 | $15 |
| Nabriva Therapeutics, PLC | 1 | $13 |
| IBSA Pharma Inc. | 1 | $13 |
| Hikma Pharmaceuticals USA | 1 | $13 |
| Sanofi Pasteur Inc. | 1 | $12 |
| Paratek Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,404 in reported general payments places this provider in the 80th percentile of 1,498 internal medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 138 | $137,375 |
| EliquisApixaban | 101 | $124,920 |
| JanuviaSitagliptin Phosphate | 53 | $54,946 |
| OzempicSemaglutide | 29 | $48,260 |
| MyrbetriqMirabegron | 89 | $38,278 |
| XareltoRivaroxaban | 22 | $33,226 |
| Breo ElliptaFluticasone/Vilanterol | 31 | $25,642 |
| JardianceEmpagliflozin | 21 | $22,301 |
| MounjaroTirzepatide | 16 | $20,725 |
| SymbicortBudesonide/Formoterol Fumarate | 43 | $20,662 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $15,768 |
| TradjentaLinagliptin | 12 | $15,464 |
| EntrestoSacubitril/Valsartan | 13 | $11,541 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 227 | $9,204 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 381 | $9,024 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Symbicort | $171 | $158,038181 claims |
| PfizerEliquis | $235 | $124,920101 claims |
| MerckJanuvia | $28 | $54,94653 claims |
| Novo NordiskOzempic | $141 | $48,26029 claims |
| GSKBreo Ellipta, Trelegy Ellipta | $114 | $41,41042 claims |
| Astellas Pharma US IncMyrbetriq | $241 | $38,27889 claims |
| Boehringer IngelheimJardiance, Tradjenta | $84 | $37,76633 claims |
| Johnson & JohnsonXarelto | $40 | $33,22622 claims |
| Lilly USA, LLCMounjaro | $58 | $20,72516 claims |
| NovartisEntresto | $131 | $11,54113 claims |
| AbbVieSynthroid | $279 | $2,44833 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,498 internal medicine providers in South Carolina.
Other internal medicine in Spartanburg
- Suzanne KovacsSpartanburg$14K
- Rica SantiagoMt Pleasant$10.7M
- Richard MillsMt Pleasant$5.5M
- Yvonne DavisMount Pleasant$2.4M
- David BolsterSummerville$2.3M
- Colby GrossmanSummerville$1.4M
- Amit ShahIndian Land$1.4M
- Philip NicolMurrells Inlet$782K
- Carl SofleyAnderson$673K
- Carl MitchellColumbia$564K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.